Table 1 Opioid Treatment Program naloxone survey results pre-training at baseline
Study sites | |||||||||
|---|---|---|---|---|---|---|---|---|---|
*SITE 1 | *SITE 2 | *SITE 3 | *SITE 4 | *SITE 5 | Site 6 | Site 7 | Site 8 | Total (%) | |
Training Participation # | 13 | 14 | 11 | 5 | 8 | 11 | 5 | 11 | 78 |
Question 1: Are you aware of NM’s HB 370? | |||||||||
Yes | 2 | 0 | 8 | 1 | 4 | 4 | 0 | 1 | 20 (25.6%) |
No | 10 | 14 | 3 | 4 | 4 | 7 | 5 | 10 | 57 (73.1%) |
No answer | 1 | 1 (1.3%) | |||||||
Question 2: Do you currently prescribe or provide take-home naloxone to your patients? (choose all that apply) | |||||||||
Write Rx | 2 | 3 | 4 | 9 (10.7%) | |||||
Provide take-home | 1 | 9 | 5 | 15 (17.8%) | |||||
Ask pts to go to pharmacy so that a pharmacist prescribes it | 6 | 2 | 3 | 3 | 2 | 1 | 17 (20.3%) | ||
None of the above | 5 | 11 | 1 | 2 | 1 | 8 | 5 | 10 | 43 (51.2%) |
Question 3: Of the following, which are barriers to dispensing naloxone at your opioid treatment program? (choose all that apply) | |||||||||
Affordability | 1 | 2 | 3 | 2 | 1 | 3 | 2 | 3 | 17 (19.8%) |
No mechanism for reimbursement | 1 | 1 | 2 | 4 (4.7%) | |||||
Unsure what type of naloxone to prescribe (nasal, auto-injector, generic) | 1 | 1 | 2 (2.3%) | ||||||
Time to educate patients | 2 | 3 | 2 | 2 | 1 | 2 | 2 | 14 (16.3%) | |
Patient refusal | 1 | 2 | 1 | 5 | 1 | 10 (11.6%) | |||
Lack of patient medical history | 1 | 1 | 2 (2.3%) | ||||||
Concerns with liability | 4 | 2 | 3 | 9 (10.5%) | |||||
Inadequate supply | 3 | 1 | 1 | 1 | 3 | 9 (10.5%) | |||
Belief that it promotes heroin and/or prescription drug abuse | 1 | 1 | 2 (2.3%) | ||||||
None of the above* | 3 | 5 | 1 | 1 | 2 | 1 | 4 | 17 (19.8%) | |
Focus group participation # | 6 | 9 | 7 | 5 | 6 | n/a | n/a | n/a | 33 |